Accuray Incorporated

Equities

ARAY

US0043971052

Advanced Medical Equipment & Technology

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-26 pm EDT			5-day change	1st Jan Change
2.185 ^USD	+0.23%		+2.10%	-22.79%

Apr. 25	Accuray Incorporated Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024	CI
Apr. 18	Accuray Incorporated Expands Global Training Center Network with Opening of New Facility in Genolier, Switzerland	CI

Accuray Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023

January 31, 2024 at 04:05 pm EST

Accuray Incorporated reported earnings results for the second quarter and six months ended December 31, 2023. For the second quarter, the company reported revenue was USD 107.24 million compared to USD 114.76 million a year ago. Net loss was USD 9.62 million compared to USD 1.87 million a year ago. Basic loss per share from continuing operations was USD 0.1 compared to USD 0.02 a year ago.
For the six months, revenue was USD 211.13 million compared to USD 211.25 million a year ago. Net loss was USD 12.59 million compared to USD 7.32 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.08 a year ago.

Latest news about Accuray Incorporated

Accuray Incorporated Showcases Advances in Radiation Therapy Solutions Designed to Improve the Cancer Treatment Experience at ESTRO 2024	Apr. 25	CI
Accuray Incorporated Expands Global Training Center Network with Opening of New Facility in Genolier, Switzerland	Apr. 18	CI
Accuray Incorporated Announces New Data from Two Clinical Studies Indicate High-Risk and Recurrent Prostate Cancers Can Be Effectively Treated in 5 Days Using the Accuray CyberKnife System	Mar. 26	CI
Roth MKM Starts Accuray With Buy Rating, $9 Price Target	Feb. 13	MT
Quebec Cancer Center Is First in Canada to Treat Cancer Patients Using the Accuray Radixact System	Feb. 13	CI
Transcript : Accuray Incorporated, Q2 2024 Earnings Call, Jan 31, 2024	Jan. 31
Earnings Flash (ARAY) ACCURAY INCORPORATED Posts Q2 Revenue $107.2M, vs. Street Est of $106.7M	Jan. 31	MT
Accuray Incorporated Reports Earnings Results for the Second Quarter and Six Months Ended December 31, 2023	Jan. 31	CI
Accuray Incorporated Reaffirms Revenue Guidance for the Third Quarter and Full Fiscal Year 2024	Jan. 31	CI
Accuray Incorporated Announces the Providence Swedish Radiosurgery Center in Seattle Invests in Second Accuray Cyberknife System	Jan. 25	CI
Accuray Insider Sold Shares Worth $161,624, According to a Recent SEC Filing	Dec. 05	MT
B. Riley Trims Accuray's Price Target to $6.50 From $7.50 on Lower Multiple, Maintains Buy Rating	Nov. 09	MT
Transcript : Accuray Incorporated, Q1 2024 Earnings Call, Nov 07, 2023	Nov. 07
Accuray Incorporated Reports Earnings Results for the First Quarter Ended September 30, 2023	Nov. 07	CI
Earnings Flash (ARAY) ACCURAY INCORPORATED Reports Q1 Revenue $103.9M, vs. Street Est of $97.6M	Nov. 07	MT
Accuray Shares Rise After Securing Approval for Tomo C Radiation Therapy System in China	23-10-04	MT
Accuray Secures Approval for Tomo C Radiation Therapy System in China	23-10-03	MT
Transcript : Accuray Incorporated - Analyst/Investor Day	23-10-03
Accuray Announces Approval of the Tomo C Radiation Treatment Delivery System by China's National Medical Products Administration	23-10-03	CI
Accuray Partners With Limbus AI to Launch Online Adaptive Therapy for Radixact System	23-10-02	MT
Accuray Incorporated and Limbus AI Unveil Online Adaptive Therapy Solution for Radixact System at American Society for Radiation Oncology Annual Meeting	23-10-02	CI
Accuray Incorporated Opens the Doors of its New Global Training Facility, the Accuray Center for Education, Located At its Corporate Headquarters in Madison, Wisconsin	23-09-18	CI
Accuray Gets US FDA Clearance for Addition of New Functionality to Radixact System for Breast Cancer Treatment	23-08-10	MT
Accuray Incorporated Receives FDA Clearance for VitalHold on the Radixact System; Breast Cancer Treatment Option Will Also Be Available in the EU Market	23-08-09	CI
Transcript : Accuray Incorporated, Q4 2023 Earnings Call, Aug 09, 2023	23-08-09

Chart Accuray Incorporated

Duration

Period

More charts

Company Profile

Accuray Incorporated is a radiation therapy company. The Company develops, manufactures, sells, and supports solutions that are designed to deliver radiation treatments. Its solutions are designed to advance patient care during each individual treatment, throughout the treatment process, and at each stage of the cancer treatment journey, from curative to palliative treatments. Its technologies, the CyberKnife and TomoTherapy platforms, including the Radixact System, its TomoTherapy platform, are designed to deliver advanced treatments, including stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), intensity modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and adaptive radiation therapy (ART). In addition to these products, the Company also provides services, which include post-contract customer support (warranty period services and post warranty services), installation services, training, and other professional services.

Sector

Advanced Medical Equipment & Technology

Calendar

2024-04-30 - Q3 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Accuray Incorporated

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.19 USD

Average target price

8.75 USD

Spread / Average Target

+299.54%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Advanced Medical Equipment & Technology

	1st Jan change	Capi.
ACCURAY INCORPORATED	-22.79%	217M
THERMO FISHER SCIENTIFIC	+8.07%	219B
DANAHER CORPORATION	+6.59%	183B
INTUITIVE SURGICAL, INC.	+11.26%	133B
BOSTON SCIENTIFIC CORPORATION	+26.57%	108B
EDWARDS LIFESCIENCES CORPORATION	+13.35%	52.02B
SHENZHEN MINDRAY BIO-MEDICAL ELECTRONICS CO., LTD.	-0.62%	48.2B
AGILENT TECHNOLOGIES, INC.	-0.93%	40.37B
GE HEALTHCARE TECHNOLOGIES INC.	+11.54%	39.35B
RESMED, INC.	+26.76%	32.03B

Other Advanced Medical Equipment & Technology